Login to Your Account



Regulatory NEWS
The FDA needs to apply the brakes on its headlong rush to adopt quality metrics for the manufacturing of drugs, the agency was told Monday.
For personalized medicine to deliver on its promise of tailoring treatments to the patient, incentives may be needed to spur the development of diagnostics that can identify those who would benefit from a specific drug.
Against a backdrop of expanding FDA approvals for opioids, several senators are going over the agency's head to enlist support to fight the accompanying opioid addiction problems.
More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: